Serum concentrations of thioridazine, its major metabolites and serum neuroleptic‐like activities in schizophrenics with and without tardive dyskinesia

Acta Psychiatrica Scandinavica - Tập 66 Số 4 - Trang 294-305 - 1982
E. Widerlöv1,2,3, J.‐E. Häggström1,2,3, Clinton D. Kilts1,2,3, Jan Andersson1,2,3, George R. Breese1,2,3, Richard B. Mailman1,2,3
1Biological Sciences Research Center (Head: Prof. M. A. Lipton), School of Medicine, University of North Carolina, Chapel Hill, NC, U.S.A.
2Clinical Psychopharmacology Laboratory, Dept. of Psychiatry (Head: Prof. H. K. H. Brodie), Duke University Medical Center, Durham, NC, U.S.A.
3Psychiatric Research Center (Head: Prof. L.M. Gunne), Ulleråker Hospital, University of Uppsala, Sweden

Tóm tắt

Two groups of elderly chronic schizophrenic patients, one with and one without tardive dyskinesia (TD), were studied. In addition to estimation of the neuroleptic‐like radioreceptor activity (RRA) of the serum, serum concentrations of thioridazine (THD) and its major metabolites, THD‐2‐sulfoxide, THD‐2‐sulfone and THD‐5‐oxide, were measured with high performance liquid chromatography. Blood samples were collected at two different occasions when the patients were considered to be in a pharmacological “steady state”. The concentrations of THD and its metabolites, as well as RRA values, were similar at both occasions. In general, THD‐2‐sulfoxide and THD‐5‐oxide were present in higher concentrations than the parent compounds, and the serum concentrations of THD, its metabolites and the RRA values were positively correlated with the administered daily dose of THD. However, no significant difference in serum levels of THD, its metabolites, or RRA values existed between the patients with and without TD. These data suggest that pharmacodynamic rather than pharmacokinetic differences may be more important in producing high risk for TD in patients on long‐term neuroleptic treatment.

Từ khóa


Tài liệu tham khảo

Axelsson R., 1977, On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side‐chain sulfoxide and thioridazine side‐chain sulfone, in chronic psychotic patients, Curr. ther. Res., 21, 587

Axelsson R., 1976, Serum concentration and elimination from serum of thioridazine in psychiatric patients, Curr. ther. Res., 19, 242

Axelsson R., 1977, The concentration pattern of nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables, Curr. ther. Res., 21, 561

Baldessarini R. J., 1980, Tardive dyskinesia: Task Force Report

Bylund D. B., 1981, Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors, J. Pharmacol. exp. Ther., 217, 81

10.1176/ajp.136.1.79

10.1016/0165-1781(79)90062-3

Costa E., 1978, Action of antischizophrenic drugs on the metabolism of γ‐aminobutyric acid and acetylcholine in globus pallidus, striatum and n. accumbens, Fed. Proc., 37, 2408

10.1038/270180a0

10.1016/0364-7722(77)90037-6

10.1016/0010-440X(78)90083-4

10.1016/0028-3908(79)90052-2

10.1007/BF00433548

Häggström J.‐E, 1980, Sulpiride in tardive dyskinesia, Curr. ther. Res., 27, 164

10.1055/s-2007-1019530

10.1176/ajp.138.3.297

10.1056/NEJM197911223012116

10.1016/0165-1781(81)90034-2

Kilts C. D., 1980, Effects of thioridazine (THD) and its metabolites on dopamine stimulated adenylate cyclase and 3H‐spiperone binding, Fed. Proc., 39, 528

Kilts C. D., 1981, Simultaneous determination of thioridazine and its sulfoxidized metabolites by HPLC: use in clinical and preclinical metabolic studies, Fed. Proc., 40, 238

10.1016/S0378-4347(00)81862-9

Kleinbaum D., 1978, Applied regression and other multivariable methods

10.1111/j.1600-0773.1982.tb00935.x

10.1192/bjp.135.6.489

10.1007/BF00558283

10.1177/009127006600600605

Sherman K. A., 1978, The effect of neuroleptics on acetylcholine concentration and choline uptake in striatum: implications for regulation of acetylcholine metabolism, J. Pharmacol. exp. Ther., 206, 677

10.1111/j.1600-0773.1981.tb01612.x

Sugerman A. A., 1965, A comparison of TPS‐23 and thioridazine in chronic schizophrenic patients, Curr. ther. Res., 7, 520